Growth Hormone Does Not Prevent Catabolic Side Effects of Dexamethasone in Extremely Low Birth Weight Preterm Infants with Bronchopulmonary Dysplasia - A Pilot Study

Autor: Giorgio Tonini, T. Pahor, Umberto de Vonderweid, F. Colonna
Rok vydání: 1997
Předmět:
Zdroj: Journal of Pediatric Endocrinology and Metabolism. 10
ISSN: 2191-0251
0334-018X
Popis: Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 +/- 3 wks, birth weight 824 +/- 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 +/- 9 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d i.v.) and subcutaneous rhGH at different doses: 0.1 (n = 1), 0.2 (n = 2) or 0.3 (n = 2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were significantly higher (p < 0.001). rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.
Databáze: OpenAIRE